Myriad Genetics, Inc. (MYGN) Revenue History
Annual and quarterly revenue from 2014 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
MYGN Revenue Growth
Revenue Breakdown (FY 2023)
MYGN's revenue distribution by segment and geography for fiscal year 2023
By Product/Segment
By Geography
MYGN Revenue Analysis (2014–2025)
As of May 8, 2026, Myriad Genetics, Inc. (MYGN) generated trailing twelve-month (TTM) revenue of $829.0 million, reflecting modest growth of +2.3% year-over-year. The most recent quarter (Q1 2026) recorded $200.4 million in revenue, down 4.5% sequentially.
Looking at the longer-term picture, MYGN's 5-year compound annual growth rate (CAGR) stands at +8.2%, indicating steady revenue expansion. The company achieved its highest annual revenue of $851.1 million in 2018.
Revenue diversification analysis shows MYGN's business is primarily driven by Testing Revenue (100%). With over half of revenue concentrated in Testing Revenue, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including NTRA (+35.9% YoY), EXAS (+17.7% YoY), and VCYT (+16.9% YoY), MYGN has underperformed the peer group in terms of revenue growth. Compare MYGN vs NTRA →
MYGN Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| MYGNCurrent | $829M | +2.3% | +8.2% | -8.2% | |
 NTRA | $2.3B | +35.9% | +42.6% | -13.4% | |
 EXAS | $3.2B | +17.7% | +16.8% | -6.4% | |
 VCYT | $517M | +16.9% | +34.5% | 14.3% | |
 CDNA | $380M | +19.2% | +14.6% | -5.5% | |
 ILMN | $4.3B | +1.2% | +6.0% | 19.9% |
MYGN Historical Revenue Data (2014–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $824.5M | -1.6% | $576.6M | 69.9% | $-67,800,000 | -8.2% |
| 2024 | $837.6M | +11.2% | $585.4M | 69.9% | $-123,500,000 | -14.7% |
| 2023 | $753.2M | +11.0% | $517.0M | 68.6% | $-257,400,000 | -34.2% |
| 2022 | $678.4M | -1.8% | $476.4M | 70.2% | $-140,600,000 | -20.7% |
| 2021 | $690.6M | +24.0% | $493.0M | 71.4% | $-190,500,000 | -27.6% |
| 2020 | $557.0M | -12.8% | $378.8M | 68.0% | $-194,800,000 | -35.0% |
| 2019 | $638.6M | -25.0% | $452.5M | 70.9% | $-231,700,000 | -36.3% |
| 2018 | $851.1M | +10.2% | $650.1M | 76.4% | $7.6M | 0.9% |
| 2017 | $772.6M | +0.2% | $595.4M | 77.1% | $118.7M | 15.4% |
| 2016 | $771.4M | +2.3% | $600.2M | 77.8% | $49.4M | 6.4% |
See MYGN's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs MYGN Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare MYGN vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonMYGN — Frequently Asked Questions
Quick answers to the most common questions about buying MYGN stock.
Is MYGN's revenue growth accelerating or slowing?
MYGN revenue growth slowed to +2.3%, below the 5-year CAGR of +8.2%. TTM revenue is $829M. The deceleration marks a shift from historical growth rates.
What is MYGN's long-term revenue growth rate?
Myriad Genetics, Inc.'s 5-year revenue CAGR of +8.2% reflects the variable expansion pattern. Current YoY growth of +2.3% is near this long-term average.
How is MYGN's revenue distributed by segment?
MYGN reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2014-2025 are available for download. Segment mix reveals concentration and diversification trends.